Gastroesophageal Reflux Disease (GERD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Gastroesophageal Reflux Disease (GERD) Market Outlook

Thelansis’s “Gastroesophageal Reflux Disease (GERD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Gastroesophageal Reflux Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Gastroesophageal Reflux Disease (GERD) Overview

Gastroesophageal reflux disease (GERD) is a chronic gastrointestinal condition that regurgitates stomach contents into the esophagus. Various mechanisms cause it, some intrinsic and some structural, to disrupt the barrier at the esophagogastric junction, exposing the esophagus to acidic gastric contents. Clinically, GERD commonly presents with symptoms like heartburn and regurgitation. However, it can manifest atypically with extra-esophageal symptoms such as chest pain, dental erosion, chronic cough, laryngitis, or asthma. GERD is categorized into three phenotypes based on endoscopic and histopathologic findings: non-erosive reflux disease (NERD), erosive esophagitis (EE), and Barrett's esophagus (BE). Individuals with asthma face a higher risk of developing GERD. Asthma exacerbations can relax the lower esophageal sphincter, allowing stomach contents to reflux into the esophagus. Some asthma medications, particularly theophylline, may exacerbate reflux symptoms. Various diagnostic tests are available for GERD, including X-rays of the upper digestive system, endoscopy to visualize the esophagus, ambulatory acid (pH) monitoring to track esophageal acid levels and esophageal impedance testing to measure substance movement in the esophagus. Treatment options encompass lifestyle changes, medical management with antacids and drugs that reduce acid secretion, surgical interventions, and endoscopic therapies. Medical therapy includes the use of antacids, histamine (H2) receptor antagonists (H2RAs), proton pump inhibitors (PPIs), and prokinetic agents. In the United States, two H2RAs (famotidine and cimetidine) are FDA-approved and available over-the-counter. Surgical management is considered for patients who do not respond to medical treatment, are noncompliant with it, experience side effects, have large hiatal hernias, or wish to discontinue long-term medical therapy.

• The global prevalence of GERD is estimated to be 9574.45 cases per 100,000 people.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: